First Tracks Biotherapeutics, Inc. (TRAX)
| Market Cap | 559.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -169.38M |
| Shares Out | 34.89M |
| EPS (ttm) | -4.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,731,941 |
| Open | 16.30 |
| Previous Close | 16.37 |
| Day's Range | 15.71 - 16.91 |
| 52-Week Range | 14.72 - 26.80 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 38.13 (+137.87%) |
| Earnings Date | Jun 1, 2026 |
About TRAX
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). Fir... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TRAX stock is "Strong Buy." The 12-month stock price target is $38.13, which is an increase of 137.87% from the latest price.
News
First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo
Wells Fargo analyst Derek Archila initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $30 price target At current share levels, the Street undervalues both ANB033’s...
First Tracks Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026
A newly independent biotech with $180 million in cash is advancing a pipeline of antibody therapies for autoimmune diseases, led by ANB033 targeting CD122. Key phase I-B trials in celiac disease and EoE are ongoing, with major data readouts expected in Q4 and mid-2027.
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathw...
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways impl...
First Tracks Biotherapeutics Earnings release: Q1 2026
First Tracks Biotherapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
First Tracks Biotherapeutics Quarterly report: Q1 2026
First Tracks Biotherapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
First Tracks Biotherapeutics Slides: Corporate presentation
First Tracks Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
First Tracks Biotherapeutics files to sell 10.5M shares of common for holders
16:38 EDT First Tracks Biotherapeutics (TRAX) files to sell 10.5M shares of common for holders
First Tracks Biotherapeutics Registration statement: Registration filing
First Tracks Biotherapeutics filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.
First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $54 price target The company has a “differentiated pipeline” across ANB033,...
First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $30 price target The company has a pipeline of clinical-stage immune cell modulatin...
First Tracks Biotherapeutics initiated with an Outperform at Leerink
Leerink analyst David Risinger initiated coverage of First Tracks Biotherapeutics (TRAX) with an Outperform rating and $46 price target. This is an event story, with multiple near-term catalysts, the ...
First Tracks Biotherapeutics initiated with an Overweight at Barclays
Barclays initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $40 price target The firm views the company’s ANB033 as an “anchor asset with significant upside potent...
First Tracks Biotherapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $31 price target The firm views First Tracks as an emerging clinical stage immunolo...
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeuti...